# A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

> **NCT06840002** · PHASE1,PHASE2 · RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** SHR-A1811
- **DRUG:** Carboplatin
- **DRUG:** Bevacizumab
- **DRUG:** Oxaliplatin for Injection
- **DRUG:** Paclitaxel injection
- **DRUG:** Doxorubicin hydrochloride liposome injection
- **DRUG:** Adebrelimab Injection

## Key facts

- **NCT ID:** NCT06840002
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-18
- **Primary completion:** 2026-05
- **Final completion:** 2026-07
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06840002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06840002, "A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06840002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*